Inclusion Criteria:

          -  Histologically confirmed diagnosis of advanced NSCLC

          -  Have not received prior systemic therapy treatment for their advanced/Stage four
             NSCLC. Completion of treatment with cytotoxic chemotherapy, biological therapy, and/or
             radiation as part of neoadjuvant/adjuvant therapy is allowed as long as therapy was
             completed at least 6 months prior to the diagnosis of metastatic disease. Confirmation
             of resolution of toxic effects of previous neoadjuvant/adjuvant chemotherapy therapy
             to Grade less than or equal to 1. For radiation toxicity or prior major surgeries,
             participants should have recovered from side effects and/or complications

          -  Have measurable disease based on RECIST 1.1

          -  Have a life expectancy of at least 3 months

          -  Availability of tumor tissue (less than 6 months old) before the first dose is
             mandatory to determine PD-L1 expression level prior to enrollment

          -  PD-L1 high status as determined by central testing

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  Participants with nonsquamous NSCLC histologies whose tumor harbors any of the
             following molecular alterations and targeted therapy is locally approved: epidermal
             growth factor receptor (EGFR) sensitizing (activating) mutation, anaplastic lymphoma
             kinase (ALK) translocation, ROS1 rearrangement, or BRAF V600E mutation

          -  Has received major surgery within 4 weeks prior to the first dose of study
             intervention; received thoracic radiation therapy of greater than 30 units of gray
             (Gy) within 6 months prior to the first dose of study

          -  Known severe hypersensitivity to investigational products (M7824 or pembrolizumab), or
             any components in their formulations

          -  Previous malignant disease (other than the target malignancy to be investigated in
             this study) within the last 3 years

          -  Other protocol defined exclusion criteria could apply